CClinicalTrials.gg
CompletedNCT02309294Updated Oct 12, 2016Results posted

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin

An interventional study of Novel lubricant Miami w/ fragrance and Novel lubricant Miami no fragrance in Cumulative Irritation, sponsored by Church & Dwight Company, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-12.

Sponsored by Church & Dwight Company, Inc. · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to determine the ability of the study material to cause irritation to the skin of humans under controlled patch test conditions. Substances that come into contact with human skin need to be evaluated for their propensity to irritate and/or sensitize. This testing is a modified primary irritancy patch test that can detect weak irritants that require multiple applications to cause a skin reaction.

02

Conditions studied

  • Cumulative Irritation

Keywords

  • Patch Test
03

In context

Lead sponsor

Church & Dwight Company, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Are a male or female, 18 years of age or older, in general good health;
  • Have normal skin;
  • Are free of any systemic or dermatologic disorder which, in the opinion of the investigative personnel, will interfere with the study results or increase the risk of adverse events;
  • Are of any skin type or race providing the skin pigmentation will allow discernment of erythema;
  • Complete a medical screening procedure; and
  • Read, understand, and sign an informed consent.

Exclusion criteria

Exclusion Criteria:

  • Have any visible skin disease at the study site which, in the opinion of the investigative personnel, will interfere with the evaluation;
  • Are receiving systematic or topical drugs or medication which, in the opinion of the investigative personnel, will interfere with the study results;
  • Have psoriasis and/or active atopic dermatitis/eczema; and/or
  • Have a known sensitivity to cosmetics, skin care products, or topical drugs as related to the material being evaluated.
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Healthy Subject

    Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).

    Device: Novel lubricant Miami w/ fragrance · Device: Novel lubricant Miami no fragrance · Device: KY Liquid lubricant · Device: Astroglide Gel lubricant · Device: Wet Platinum lubricant

Interventions

  • DeviceNovel lubricant Miami w/ fragrance

    0.2 ml aliquot on occlusive patch

  • DeviceNovel lubricant Miami no fragrance

    0.2 ml aliquot on occlusive patch

  • DeviceKY Liquid lubricant

    0.2 ml aliquot on occlusive patch

  • DeviceAstroglide Gel lubricant

    0.2 ml aliquot on occlusive patch

  • DeviceWet Platinum lubricant

    0.2 ml aliquot on occlusive patch

06

What researchers measure

Primary outcomes

  1. Number of Subjects That Showed no Significant Irritation

    Score of less than or equal to 1.2 on the Cumulative Irritation Test scale (0-5).

    Time frame: 14 days

07

Results

Posted Oct 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneHealthy Subject
Started43
Completed41
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Subjects That Showed no Significant Irritation

Score of less than or equal to 1.2 on the Cumulative Irritation Test scale (0-5).

Time frame:
14 days
Reported as:
Number · participants
Number of Subjects That Showed no Significant Irritation
participantsHealthy Subject
Number of Subjects That Showed no Significant Irritation0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Subject—0/41 (0%)0/41 (0%)

Baseline characteristics

Age, Customized
Age, Customized(participants)Healthy Subject
20-7241
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Subject
Female31
Male10
08

Study locations

1 site
  • TKL Research, Inc.
    Fair Lawn, New Jersey 07410, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02309294
Lead sponsor
Church & Dwight Company, Inc.
Responsible party
Sponsor
First posted
Dec 5, 2014
Start date
Dec 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Oct 12, 2016
Last update
Oct 12, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion